News

Santé log21m
Unnatural Products Announces Multi-Target Collaboration with argenx to Develop Oral Macrocyclic Peptide Therapeutics
UNP’s platform combines AI-guided compound design, massively parallel synthesis, and direct-to-biology screening, enabling the rapid generation of drug-like macrocycles that bind challenging targets ...
Santé log21m
Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)
Under the terms of the agreement, Sobi will acquire 90% of Apellis’ ex-U.S. royalties for Aspaveli for $275 million in cash. Apellis will also be eligible for up to $25 million in milestone payments ...
Santé log21m
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Surpasses 50% Enrollment Target
Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the Phase 2 ‘START’ Study ...
Santé log21m
EDAP Announces Transition from Foreign Private Issuer to U.S. Domestic Filer Status
Transition to U.S. reporting status to take effect on January 1, 2026 ...
Santé log21m
Genmab Announces Changes to its Executive Committee
Greg joins Genmab from AstraZeneca (AZ), where he spent more than 20 years working in North America, Europe and Asia. For the last 12 years, he was part of the Legal Senior Management Team, holding ...
Santé log21m
Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®
Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and ...